Rapamycin for Longevity: What the Evidence Shows

Rapamycin (sirolimus) is a bacterial macrolide originally discovered in soil samples from Easter Island. It inhibits mTORC1, the master regulator of cellular growth and metabolism. In animal studies, it is the single most reproducible life-extension intervention ever tested: extending median lifespan in mice by 10 to 25% across multiple independent studies, even when started late in life. In humans, the evidence is promising but incomplete.

The mTOR Mechanism

mTOR (mechanistic target of rapamycin) integrates signals from nutrients, growth factors, and cellular energy status to decide whether cells should grow, divide, or enter maintenance and repair mode. When mTOR is chronically elevated (as it is in states of overnutrition), cells prioritize growth over repair. Autophagy, the cellular cleanup process that clears damaged proteins and organelles, is suppressed.

Rapamycin inhibits mTORC1, shifting cells from growth mode to maintenance mode. This upregulates autophagy, improves cellular proteostasis, and reduces senescent cell burden. All of these effects are associated with slower biological aging.

Animal Evidence

The NIA Interventions Testing Program found rapamycin extended lifespan by 9 to 14% in male and female mice when started at 20 months of age (equivalent to roughly 60 years in humans). Subsequent studies found even larger effects with earlier initiation. Rapamycin also extended health span in these animals, reducing cancer incidence, preserving cardiac function, and maintaining cognitive performance longer.

The same life-extension has been replicated in fruit flies, roundworms, and yeast, making mTOR inhibition one of the most conserved aging pathways across species.

Human Evidence

Direct longevity evidence in healthy humans does not yet exist because such studies would take decades. However, several relevant data points have emerged.

The PEARL trial (2022) tested low-dose intermittent rapamycin (5 to 10mg weekly) in healthy older adults and found improvements in immune function (specifically, reduced immunosenescence markers), without significant immunosuppressive side effects at the doses tested.

Joan Mannick at resTORbio conducted trials using rapalog compounds in older adults and found significant improvement in vaccine responses, a validated marker of immune aging. A 2014 NEJM paper showed 6 weeks of rapalog treatment improved flu vaccine response by 20%.

Peter Attia, David Sinclair, and other prominent longevity researchers have publicly discussed their personal use of low-dose weekly rapamycin, typically 2 to 6mg once weekly. This is off-label use.

Dosing in the Longevity Context

The key insight from the animal literature is that intermittent dosing (allowing mTORC1 to partially recover between doses) may capture longevity benefits while minimizing immunosuppressive effects. Daily rapamycin at transplant doses (2 to 5mg daily) causes significant immune suppression. Weekly dosing at 2 to 6mg appears to provide mTOR inhibition benefits with a much more favorable safety profile.

No formal dosing consensus exists for healthy aging use. Most longevity physicians prescribing off-label use once-weekly protocols.

Risks and Unknowns

Rapamycin is not without risk. Known side effects at chronic low doses include mouth sores (aphthous ulcers), potential impairment of mTORC2 (which has important metabolic functions including insulin signaling), and theoretical concerns about muscle protein synthesis suppression with very frequent dosing.

mTORC2 inhibition is a significant concern: chronic rapamycin use in rodents can cause insulin resistance by impairing mTORC2-dependent glucose metabolism. This is less of a concern with intermittent weekly dosing.

FAQ

Q: Can I buy rapamycin over the counter? A: No. Rapamycin is a prescription medication in the US, EU, and most countries. It requires a physician prescription. Several longevity-focused clinics prescribe it off-label for aging.

Q: Should I take rapamycin with or without other supplements? A: If using rapamycin, avoid grapefruit (inhibits CYP3A4 metabolism). NAD+ precursors, senolytics, and other longevity interventions are often combined, but no formal combination protocols have been studied in humans.

Q: Is rapamycin safe for people without transplants? A: At the low intermittent doses used in longevity contexts, the available evidence suggests an acceptable short-term safety profile, but long-term safety data in healthy individuals is limited. It should only be used under physician supervision with regular monitoring.

Track your supplements in Optimize.